

CHEMICAL CONSTITUENTS FROM THE ANTITUMOR FRACTION OF *Trachyrhamphus serratus*

Mengyue Wang, Yunjin He, Yuxiao Nie, and Xiaobo Li*

UDC 547.918

Trachyrhamphus serratus Temminck et Schlegel, a pipefish widely distributing in Western Pacific Ocean and Northern Indian Ocean, has been used for the treatment of impotence and tumor for more than 500 years in China [1, 2]. It was reported that the ethanol extract of *Trachyrhamphus serratus* showed obvious antitumor activity *in vivo* [3] and *in vitro* [4]. Moreover, the active components were confirmed in the petroleum ether soluble fraction of the ethanol extract according to active-guided screening in our preliminary studies [5]. In order to find the antitumor constituents, chemical separation was carried out on the petroleum ether fraction. As a result, 12 compounds were isolated and identified, including a new natural product **9**. Compounds **2–12** were obtained from *Trachyrhamphus serratus*, and compound **6** was found in the vertebrate for the first time.

The dried *Trachyrhamphus serratus* was obtained from Haikou, Hainan province of China, in November, 2005 and was authenticated by one of the authors, Prof. Xiaobo Li. The whole body of *Trachyrhamphus serratus* (517 g) was extracted with 95% alcohol by reflux for three times (2 h each time) and filtered. The ethanol extract (69.3 g) was partitioned with water and petroleum ether (30–60°C). The petroleum ether soluble fraction was evaporated to yield the petroleum ether extract (31.8 g). Part of the petroleum ether extract (26.4 g) was chromatographed on a silica gel column (mesh 200–300) and subjected to preparative TLC and preparative HPLC to afford compounds **1–12**.

Cholesterol (1). C₂₇H₄₆O, white needle, mp 147–149°C; EI-MS *m/z* 386 [M]⁺; ¹H and ¹³C NMR spectral data were consistent with those reported in the literature [6].

Oleic Acid (2). C₁₈H₃₄O₂, yellow oil; EI-MS *m/z* 282 [M]⁺; ¹H NMR spectral data were consistent with those reported in the literature [7].

Cholesteryl Stearate (3). C₄₅H₈₀O₂, white needle, mp 80–81°C; EI-MS *m/z* 652 [M]⁺. ¹H and ¹³C NMR spectral data agreed with those reported in [8].

Cholesteryl Myristate (4). C₄₁H₇₂O₂, white powder, mp 70–72°C; EI-MS *m/z* 596 [M]⁺. ¹H and ¹³C NMR spectral data agreed with those reported in [9].

1-Triacontanol (5). C₃₀H₆₂O, white powder, mp 77–79°C; ESI-MS *m/z* 439.8 [M + H]⁺. ¹H NMR (400 MHz, CDCl₃, δ, J/Hz): 0.90 (3H, t, J = 6.6, H-30), 1.60 (2H, m, H-2), 3.68 (2H, t, J = 6.6, H-1). ¹³C NMR (100 MHz, CDCl₃, δ): 63.1 (C-1), 33.1 (C-2), 25.9 (C-3), 29.5–29.9 (C-4–C-27), 32.1 (C-28), 22.7 (C-29), 14.3 (C-30) [10].

24-Ethylcholesta-4,24(28)-dien-3-one (6). C₂₉H₄₆O, white needle, mp 86–87°C. EI-MS *m/z* 410 [M]⁺. ¹H NMR (400 MHz, CDCl₃, δ, J/Hz): 0.72 (3H, s, 18-CH₃), 0.98 (3H, d, J = 6.6, 21-CH₃), 1.00 (6H, dd, J = 6.7, 1.2, 26-CH₃ and 27-CH₃), 1.15 (3H, s, 19-CH₃), 1.59 (3H, d, J = 6.6, 29-CH₃), 5.20 (1H, q, J = 6.6, H-28), 5.75 (1H, s, H-4). ¹³C NMR (100 MHz, CDCl₃, δ): 35.8 (C-1), 34.1 (C-2), 199.0 (C-3), 123.4 (C-4), 171.4 (C-5), 33.0 (C-6), 32.3 (C-7), 35.6 (C-8), 53.9 (C-9), 38.8 (C-10), 21.2 (C-11), 39.7 (C-12), 42.5 (C-13), 66.0 (C-14), 24.3 (C-15), 28.3 (C-16), 56.0 (C-17), 12.0 (C-18), 17.5 (C-19), 36.5 (C-20), 18.8 (C-21), 35.3 (C-22), 25.8 (C-23), 147.1 (C-24), 34.9 (C-25), 22.2 (C-26), 22.4 (C-27), 115.8 (C-28), 13.3 (C-29) [11].

Cholest-4-en-3-one (7). C₂₇H₄₄O, white needle, mp 79–80°C; EI-MS *m/z* 384 [M]⁺. ¹H and ¹³C NMR spectral data agreed with those reported in [12].

Squalene (8). C₃₀H₅₀, colorless oil; EI-MS *m/z* 410 [M]⁺; ¹H and ¹³C NMR spectral data were consistent with those reported in the literature [13].

School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, P. R. China, fax: 86 21 34204804, e-mail: xbli@sjtu.edu.cn. Published in Khimiya Prirodnikh Soedinenii, No. 3, pp. 413–414, May–June, 2011. Original article submitted January 6, 2010.

Cholest-5-en-3 β ,7 α -diol, 3-oleate (9). C₄₅H₇₈O₃, white needle, mp 44–46°C; EI-MS *m/z* 666 [M]⁺. Alkaline hydrolysis yielded cholest-5-en-3 β ,7 α -diol and compound **2**; IR (KBr, v, cm⁻¹): 2960 (C=C), 1738 (C=O), 1636 (C=C), 1380 (CH₃), 1182 (C-O-C). ¹H NMR (400 MHz, CDCl₃, δ , J/Hz): 0.68 (3H, s, 18-CH₃), 0.92 (3H, d, J = 6.6, 21-CH₃), 1.15 (3H, s, 19-CH₃), 3.86 (1H, br.s, H-7), 4.62 (1H, m, H-3), 5.30 (2H, m, H-9' and H-10'), 5.41 (1H, d, J = 4.4, H-6). ¹³C NMR (100 MHz, CDCl₃, δ): 37.2 (C-1), 29.4 (C-2), 74.6 (C-3), 40.1 (C-4), 146.2 (C-5), 122.1 (C-6), 68.0 (C-7), 35.6 (C-8), 42.3 (C-9), 37.7 (C-10), 21.0 (C-11), 39.4 (C-12), 42.4 (C-13), 49.5 (C-14), 24.4 (C-15), 28.4 (C-16), 56.1 (C-17), 11.8 (C-18), 18.6 (C-19), 36.0 (C-20), 19.0 (C-21), 36.4 (C-22), 24.0 (C-23), 39.8 (C-24), 28.2 (C-25), 22.8 (C-26), 23.0 (C-27), 173.4 (C-1'), 34.5 (C-2'), 24.6 (C-3'), 129.6 (C-9'), 129.8 (C-10'), 29.9–28.7 (C-4'–C-7', C-12'–C-15'), 31.6 (C-16'), 22.5 (C-17'), 14.0 (C-18') [14].

Cholest-5-en-3 β -ol-7-one (10). C₂₇H₄₄O₂, white needle, mp 165–167°C; EI-MS *m/z* 400 [M]⁺. ¹H and ¹³C NMR spectral data agreed with those reported in [15].

Hexadecanoic Acid, 2,3-Dihydroxypropyl Ester (11). C₁₉H₃₈O₄, white needle, mp 68–69°C; EI-MS *m/z* 330 [M]⁺. ¹H and ¹³C NMR spectral data agreed with those reported in [16].

Cholest-4-en-6 β -ol-3-one (12). C₂₇H₄₄O₂, white needle, mp 175–177°C; EI-MS *m/z* 400 [M]⁺. ¹H and ¹³C NMR spectral data agreed with those reported in [17].

ACKNOWLEDGMENT

This work was supported by the National Natural Science Foundation of China (No. 30672620) and the Shanghai Scientific Committee – Korea SK Research & Development Foundation (No.200312t).

REFERENCES

1. X. M. Zhao, *A Supplement to Compendium of Materia Medica*. People's Medical Publishing House, Beijing, 1957, 355 pp.
2. Hunan Province Health Department, *Traditional Chinese Medicine Standard of Hunan Province*, Science and Technology Publishing Press of Hunan Province, Changsha, 1993, 257 pp.
3. Z. H. Zhang, G. Q. Ni, L. Y. Wu, Q. Wang, L. S. Xu, and G. J. Xu, *Chin. J. Mar. Drugs*, **17**, 10 (1998).
4. S. M. Li, X. D. Wu, S. Zeng, L. J. Luan, and Q. Shao, *J. Chin. Med. Mater.*, **26**, 198 (2001).
5. M. Y. Wang, S. X. Qing, Z. H. Zhang, and X. B. Li, *Chin. Trad. Herb. Drugs*, **38**, 673 (2007).
6. J. S. Huang, Q. X. Li, J. Wu, and S. Zhang, *Chin. Trad. Herb. Drugs*, **35**, 485 (2004).
7. S. W. Liu, H. Z. Fu, and H. W. Lin, *Chin. Trad. Herb. Drugs*, **30**, 161 (1999).
8. Q. Wang, Z. H. Zhang, X. X. Zhang, and G. J. Xu, *J. Chin. Pharm. Univ.*, **29**, 24 (1998).
9. H. Tang, P. Cheng, H. W. Lin, W. Gao, and Y. Lu, *J. Chin. Med. Mater.*, **30**, 655 (2007).
10. W. Wang, W. Chen, H. B. Chen, J. Q. Liu, and Y. Y. Zhao, *J. Peking Univ. (Health Sci.)*, **33**, 205 (2001).
11. J. H. Sheu, G. H. Wang, P. J. Sung, and C. Y. Duh, *J. Nat. Prod.*, **62**, 224 (1999).
12. Z. H. Yuan, L. J. Han, H. Su, D. Y. Shi, J. Sun, S. Li, and J. G. Shi, *Chin. J. Oceanol. Limnol.*, **26**, 190 (2008).
13. H. P. He, Y. Z. Cai, M. Sun, and H. Corke, *J. Agric. Food Chem.*, **50**, 368 (2002).
14. Y. C. Zhan, L. Chen, Y. Sun, N. Zhang, Y. H. Pei, *J. Shenyang Pharm. Univ.*, **23**, 558 (2006).
15. G. Nataro, V. Piccialli, and D. Sica, *J. Nat. Prod.*, **55**, 1588 (1992).
16. D. S. Zhang, S. W. Huang, H. Y. Gao, B. H. Sun, J. Huang, and L. J. Wu, *J. Shenyang Pharm. Univ.*, **25**, 454 (2008).
17. L. Y. Li, Z. W. Deng, H. Z. Fu, H. W. Lin, and P. Proksch, *J. Asian Nat. Prod. Res.*, **7**, 115 (2005).